EOS-301984
- Generic Name
- EOS-301984
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- iTeos Therapeutics
- Target Recruit Count
- 84
- Registration Number
- NCT06547957
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪CHU de Liège, Liège, Belgium
🇧🇪Universitair Ziekenhuis Gent, Ghent, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath